Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hui Kong Gan"'
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen li
Externí odkaz:
https://doaj.org/article/75bd5259ae494948a7493d5c5e2d644f
Autor:
Sze Ting Lee, Niall Tebbutt, Hui Kong Gan, Zhanqi Liu, John Sachinidis, Kunthi Pathmaraj, Andrew Mark Scott
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionTumor hypoxia and angiogenesis are implicated in tumor growth and metastases, and anti-angiogenic therapies have an important role in treating patients with metastatic colorectal cancer. However, the prevalence of hypoxia has not been ful
Externí odkaz:
https://doaj.org/article/f8cf3dbca693425ca78964b7071b7db1
Autor:
Hui Kong Gan, Bryan W. Day, Rosemary Harrup, Terrance G. Johns, Zarnie Lwin, Andrew Mark Scott, Hao-Wen Sim, Eng-Siew Koh
Publikováno v:
Current Oncology Reports. 25:589-598
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b2409778aab19f83bc7a150ac9b2564
https://doi.org/10.1007/s11912-023-01394-5
https://doi.org/10.1007/s11912-023-01394-5
Autor:
Ashray Gunjur, Adithya Balasubramanian, Umbreen Hafeez, Siddharth Menon, Lawrence Cher, Sagun Parakh, Hui Kong Gan
Publikováno v:
Journal of neuro-oncology. 159(3)
Limited progress has been made in treating glioblastoma, and we hypothesise that poor concordance between preclinical and clinical efficacy in this disease is a major barrier to drug development. We undertook a systematic review to quantify this issu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5e70c1069c318b8868a22d296078034
https://pubmed.ncbi.nlm.nih.gov/35994157
https://pubmed.ncbi.nlm.nih.gov/35994157
Autor:
Adithya Balasubramanian, George Iatropoulos, Samantha Bowyer, Hui Kong Gan, Anne P Long, Michael Bynevelt, Graeme Jackson, Seon Young Lee, Weon Sup Lee, Jinsan Yoo, Anna Nowak, Lawrence Cher
Introduction The VEGF pathway remains an important target in GBM given its vascularity and autocrine VEGF signalling. Olinvacimab is a fully humanised VEGFR2 monoclonal antibody that binds and inhibits the receptor. This report assesses the safety, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::172ce5fb1cba640a00545a825f6dc014
https://doi.org/10.21203/rs.3.rs-1668912/v1
https://doi.org/10.21203/rs.3.rs-1668912/v1
Autor:
Ashray Gunjur, Adithya Balasubramanian, Umbreen Hafeez, Siddharth Menon, Lawrence Cher, Sagun Parakh, Hui Kong Gan
Publikováno v:
Journal of Neuro-Oncology. 159:551-551
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81621de5532b9e96b21d3f1176cfa8f8
https://doi.org/10.1007/s11060-022-04119-z
https://doi.org/10.1007/s11060-022-04119-z
Autor:
Ingrid Julienne Georgette, Burvenich, Yit Wooi, Goh, Nancy, Guo, Hui Kong, Gan, Angela, Rigopoulos, Diana, Cao, Zhanqi, Liu, Uwe, Ackermann, Christian Werner, Wichmann, Alexander Franklin, McDonald, Nhi, Huynh, Graeme Joseph, O'Keefe, Sylvia Jie, Gong, Fiona Elizabeth, Scott, Linghui, Li, Wanping, Geng, Anup, Zutshi, Yan, Lan, Andrew Mark, Scott
Publikováno v:
European journal of nuclear medicine and molecular imaging. 48(10)
Τhis study aimed to optimize theBintrafusp alfa (anti-PD-L1 human IgG1 antibody fused to TGF-β receptor II (TGF-βRII), avelumab (anti-PD-L1 human IgG1 control antibody), isotype control (mutated inactive anti-PD-L1 IgG1 control antibody), and trap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aa1fe6362e079eb1d56756ea2c08ef25
https://pubmed.ncbi.nlm.nih.gov/33608805
https://pubmed.ncbi.nlm.nih.gov/33608805
Autor:
Hui Kong Gan, Matthew E. Burge, Benjamin J. Solomon, Kyle D. Holen, Yumin Zhang, Marika Ciprotti, Thomas Merdan, Wijith Munasinghe, Michelle Pedersen, Patricia F. Hintzman, Gerard B. Fox, Rod A. Humerickhouse, Andrew Mark Scott
Publikováno v:
Journal of Clinical Oncology. 31:2520-2520
2520 Background: ABT-806 is a humanized antibody targeting a conformationally exposed epitope only available when tumor Epidermal Growth Factor Receptor (EGFR) is overexpressed or (EGFRvIII) mutated. A prior trial treated 8 patients (pts) with a chim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51e01df60b7f31f0ee2b84b3d60c36db
https://doi.org/10.1200/jco.2013.31.15_suppl.2520
https://doi.org/10.1200/jco.2013.31.15_suppl.2520